Letter Re: Oral cavity adjuvant therapy—a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity

Abstract

We read the article by Laskar et al. [ [1] Laskar S.G. Chaukar D. Deshpande M. et al. Oral cavity adjuvant therapy (OCAT)—a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavity. Eur J Cancer. 2023; 181: 179-187 Google Scholar ] with great interest. In this phase III randomised trial, patients with resected advanced-stage oral cavity squamous cell carcinoma (OCSCC) were randomised to adjuvant standard radiotherapy, concurrent chemoradiotherapy and accelerated radiotherapy arms. The authors concluded that intensification of treatment did not improve the oncologic outcomes. Yet there are some points to be clarified. Oral cavity adjuvant therapy (OCAT) -a phase III, randomized controlled trial of surgery followed by conventional RT (5 fr/wk) versus concurrent CT-RT versus accelerated RT (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavityEuropean Journal of CancerVol. 181PreviewLimited data exists regarding the impact of intensification of adjuvant therapy in resected Oral Cavity Squamous Cell Carcinomas (OCSCC) with adverse prognostic features on histopathology. Full-Text PDF Response to letter entitled: Re: Oral cavity adjuvant therapy (OCAT) - a phase III, randomised controlled trial of surgery followed by conventional radiotherapy (5 fr/wk) versus concurrent CT-RT versus accelerated radiotherapy (6fr/wk) in locally advanced, resectable, squamous cell carcinoma of oral cavityEuropean Journal of CancerPreviewWe thank Gozde Yazici et al. for their insightful comments on the publication. Full-Text PDF